IDYA
IDYA
NASDAQ · Biotechnology

Ideaya Biosciences Inc

$30.78
-1.58 (-4.88%)
As of Nov 5, 8:40 PM ET ·
Financial Highlights (FY 2026)
Revenue
223.25M
Net Income
-116,057,215
Gross Margin
—
Profit Margin
-52.0%
Rev Growth
+62.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 60.1% 60.1%
Operating Margin -72.8% -65.6% -18.9% -18.0%
Profit Margin -52.0% -49.4% -21.1% -18.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 223.25M 137.35M 384.15M 440.58M
Gross Profit — — 230.71M 264.60M
Operating Income -162,617,960 -90,043,167 -72,666,854 -79,390,880
Net Income -116,057,215 -64,262,023 -80,984,777 -83,452,264
Gross Margin — — 60.1% 60.1%
Operating Margin -72.8% -65.6% -18.9% -18.0%
Profit Margin -52.0% -49.4% -21.1% -18.9%
Rev Growth +62.5% +62.5% -7.8% +21.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 452.34M 383.43M
Total Equity — — 2.04B 2.12B
D/E Ratio — — 0.22 0.18
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -159,864,320 -93,436,141 -85,173,040 -109,288,960
Free Cash Flow — — -100,075,430 -111,173,636